Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report of the BE-1603 study

Pathologie Biologie

Volumn 61, Issue 2, 2013, Pages

  Focan, C ^a   Kreutz, F ^a   Graas, M P ^a   Longree L ^a   Focan Henrard, D ^a   Demolin, G ^a   Moeneclaey, N ^a  

^a Clinique Saint Joseph   (Belgium)

Author keywords

Ambulatory medicine; Chronotherapy; Colorectal cancer; Combination chemotherapy; Irinotecan

Indexed keywords

CARBOPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; AGRANULOCYTOSIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONOTHERAPY; COLORECTAL CARCINOMA; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEMOGLOBINOPATHY; HUMAN; LEUKOCYTE DISORDER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SKIN DISEASE; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG CHRONOTHERAPY; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84876740814     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2010.12.005     Document Type: Article

References (23)

1. Cunningham D., Pyrhonen S., James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413-1418.
2. De Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 16:2938-2947.
3. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
4. Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000, 18:136-147.
5. Rougier P., van Cutsem E., Bajetta E., et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 352:1407-1412.
6. Saltz L.B., Cox J.V., Blancke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study group. N Engl Med 2000, 343:905-914.
7. Tournigand C., André T., Achille E., et al. Folfiri followed by Folfox 6 or the reverse sequence in advanced colorectal cancer: a randomized Gercor study. J Clin Oncol 2004, 22:229-237.
8. Focan C. Circadian rhythms and cancer chronotherapy. Pharmacol Ther 1995, 67:1-52.
9. Focan C. Rhythms of cancer chemotherapy. Chronotherapeutics 2003, 235-282. Pharmaceutical Press, London. P. Redfern (Ed.).
10. Lévi F., Zidani R., Vannetzel J.M., et al. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multi-institutional trial. J Natl Cancer Inst 1994, 86:1608-1617.
11. Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as fist-line treatment of metastatic colorectal cancer. Classic Papers and Current Comments. J Clin Oncol 2002, 6:885-897.
12. Giacchetti S., Bjarnason G., Garufi C., et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organization for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006, 24:3562-3569.
13. Lévi F., Zidani R., Misset J.L. Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997, 350:681-686.
14. Lévi F., Focan C., Karaboué A., et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Advanced Drug Delivery Reviews 2007, 59(9-10):1015-1035.
15. Focan C., Kreutz F., Focan-Henrard D., et al. Chronotherapy with 5-fluorouracil, folinic acid and carboplatin for metastatic colorectal cancer; an interesting therapeutic index in a phase II trial. Eur J Cancer 2000, 36:341-347.
16. Focan C., Kreutz F., Longree L., et al. Chronotherapie associant le 5-fluorouracile, l'acide folinique, et le carboplatine en première ligne thérapeutique dans le cancer colorectal métastatique. Une étude de phase 2. Pathol Biol 2005, 53:273-276.
17. Kerr D.J., Lewis C., O'Neil B., et al. The myelotoxicity of carboplatin is influenced by the time of its administration. Hematol Oncol 1990, 8:59-63.
18. Garufi C., Bria E., Banni B., et al. A phase II study of irinotecan plus chronomodulated oxaliplatin, 5 flouoruracil and folinic acid in advanced colorectal cancer patients. Br J Cancer 2003, 89(10):1870-1875.
19. Masi G., Allegrini G., Cupini S., et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol 2004, 15(12):1766-1772.
20. Souglakos J., Androulakis N., Syrigos K., et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006, 94(6):798-805.
21. Granda T.G., D'Attino R.M., Filipski E., et al. Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br J Cancer 2002, 86:999-1005.
22. Giacchetti S., Curé H., Adenis A., et al. Randomized multicenter trial of irinotecan chronomodulated versus standard infusion in patients with metastatic colorectal cancer. Proc ASCO 2001, 20:117b.
23. Focan C., Kreutz F., Graas M.P., et al. étude de faisabilité (Phase I-II) d'une quadruple combinaison associant le 5-fluorouracile, l'acide folinique et le carboplatine à de l'irinotecan administrés en infusion chronomodulée pour le traitement du cancer colorectal avancé. Pathol Biol 2005, 53:277-280.